nphp3 Antibody

What is NPHP3 and why is it significant in research?

NPHP3 (nephronophthisis 3) is a 1330 amino acid protein with a calculated molecular weight of 151 kDa that functions as part of the ciliary network. It is expressed in primary cilia, basal bodies, and centrosomes, playing crucial roles in kidney development and function. NPHP3 has gained significant research interest because mutations in the NPHP3 gene cause nephronophthisis, the most frequent genetic cause of end-stage renal failure in children and young adults. In some cases, NPHP3 mutations are associated with tapetoretinal degeneration (Senior-Loken syndrome) and liver fibrosis . Furthermore, complete loss of NPHP3 function results in more severe phenotypes including situs inversus, congenital heart defects, and embryonic lethality in mice, highlighting its critical role in early development and left-right patterning . These diverse phenotypes make NPHP3 an important target for understanding ciliopathies and developmental disorders.

What applications is the NPHP3 antibody validated for?

NPHP3 antibody has been validated for multiple experimental applications, allowing researchers to investigate this protein in various contexts. The antibody has demonstrated positive results in the following applications:

The antibody has been specifically validated in multiple publications, including 1 for Western blot, 1 for immunohistochemistry, and 5 for immunofluorescence applications . It's important to note that optimal dilutions may vary depending on your specific experimental conditions and sample types.

What species reactivity does the NPHP3 antibody demonstrate?

The NPHP3 antibody shows reactivity with multiple mammalian species, making it suitable for comparative studies across model organisms. Documented reactivity includes:

• Human: Confirmed in multiple tissue types including testis and heart tissue

• Mouse: Validated in testis and liver tissue

• Rat: Reported reactivity, though specific tissues may need validation

• Canine: Reported reactivity, particularly in MDCK cells for immunofluorescence

This broad species reactivity makes the antibody valuable for translational research, allowing researchers to correlate findings between animal models and human samples. When working with species not explicitly listed, preliminary validation experiments are recommended before proceeding with full-scale studies.

How should I optimize Western blot conditions for NPHP3 detection?

Optimizing Western blot conditions for NPHP3 detection requires careful consideration of several parameters due to the protein's relatively high molecular weight (observed at 145-151 kDa) . For optimal results:

• Sample preparation: Use a protease inhibitor cocktail in lysis buffers to prevent degradation. For tissues with high protease content (e.g., pancreas), consider adding additional inhibitors.

• Gel selection: Use lower percentage (6-8%) SDS-PAGE gels to achieve better separation of high molecular weight proteins. Consider gradient gels (4-15%) for improved resolution.

• Transfer conditions: For large proteins like NPHP3, extend transfer time or use wet transfer methods with lower voltage over longer periods (e.g., 30V overnight at 4°C) to ensure complete transfer.

• Antibody concentration: Start with a 1:1000 dilution for Western blot applications, then adjust based on signal intensity . For weaker signals, antibody concentration can be increased to 1:500.

• Blocking conditions: Use 5% non-fat dry milk or BSA in TBS-T (pH 7.3-7.4) for blocking. For higher specificity, consider testing both blocking agents.

• Detection method: Enhanced chemiluminescence (ECL) systems are recommended, with exposure times adjusted according to signal strength.

• Positive controls: Include mouse testis tissue or HEK-293 cell lysates as positive controls, as these have been confirmed to express detectable levels of NPHP3 .

Remember that NPHP3 may show tissue-specific post-translational modifications that might affect migration patterns on gels.

What are the optimal fixation and permeabilization methods for NPHP3 immunofluorescence?

For optimal immunofluorescence detection of NPHP3, particularly in ciliary structures, the following fixation and permeabilization protocols are recommended:

• Primary fixation method: Methanol fixation has proven effective for NPHP3 visualization, particularly in hTERT-RPE1 cells . This method is optimal for preserving ciliary structures.

• Alternative fixation: If methanol fixation yields suboptimal results, try 4% paraformaldehyde (PFA) for 10 minutes at room temperature, followed by permeabilization.

• Permeabilization: For PFA-fixed samples, permeabilize with 0.1-0.2% Triton X-100 in PBS for 10 minutes at room temperature. This step is not necessary for methanol-fixed samples as methanol both fixes and permeabilizes.

• Antigen retrieval: For tissue sections, particularly paraffin-embedded samples, antigen retrieval with TE buffer (pH 9.0) is recommended. Alternatively, citrate buffer (pH 6.0) may be used .

• Antibody dilution: Begin with a 1:50 dilution for immunofluorescence applications , then optimize based on signal-to-noise ratio.

• Incubation conditions: Incubate with primary antibody overnight at 4°C for optimal binding and specificity.

• Counterstaining: For ciliary studies, co-stain with acetylated tubulin or gamma-tubulin to mark ciliary axonemes or basal bodies, respectively.

Note that validation studies have confirmed NPHP3 localization to the base and lower half of cilia in serum-starved hTERT-RPE1 cells , which should be considered when interpreting staining patterns.

How can I validate the specificity of NPHP3 antibody in my experimental system?

Validating antibody specificity is crucial for reliable research outcomes. For NPHP3 antibody, implement these validation strategies:

• Positive and negative controls: Include tissues known to express NPHP3 (e.g., testis, kidney) as positive controls, and tissues with minimal expression as negative controls. HEK-293 cells and mouse testis tissue have been validated as reliable positive controls .

• siRNA or CRISPR knockout: Use RNA interference or CRISPR-Cas9 gene editing to deplete NPHP3 in your experimental system, confirming signal reduction or elimination.

• Overexpression studies: Express tagged NPHP3 constructs and confirm co-localization with antibody staining.

• Multiple antibody approach: When possible, validate findings using a second NPHP3 antibody targeting a different epitope.

• Western blot validation: Confirm the antibody detects a band of the expected molecular weight (145-151 kDa) in your experimental system before proceeding with other applications.

• Immunoprecipitation validation: For interaction studies, verify that the antibody can specifically immunoprecipitate NPHP3 from lysates, as demonstrated in mouse testis tissue .

• Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide to confirm signal specificity.

These validation approaches should be documented and reported in publications to strengthen the reliability of your findings.

How can I use NPHP3 antibody to investigate ciliopathies?

NPHP3 antibody offers powerful approaches for studying ciliopathies, disorders resulting from ciliary dysfunction:

• Disease model verification: Use NPHP3 antibody to confirm altered protein expression, localization, or modification in tissue samples from patients with nephronophthisis, Senior-Loken syndrome, or Meckel syndrome. Changes in staining patterns can help verify disease models before further analysis.

• Tissue-specific expression profiling: Apply immunohistochemistry with the NPHP3 antibody (dilution 1:20-1:200) to analyze expression patterns across affected tissues, as NPHP3 mutations can cause phenotypes in kidneys, retina, liver, and heart . This can help determine which tissues might be affected in specific patient cohorts.

• Subcellular localization studies: Use high-resolution confocal microscopy with NPHP3 antibody to examine changes in ciliary localization in disease states. Validated in hTERT-RPE1 cells, the antibody has confirmed NPHP3 localization to the base and lower half of cilia .

• Molecular interaction networks: Employ NPHP3 antibody for co-immunoprecipitation studies (using 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate) to identify altered protein interactions in ciliopathy models, as demonstrated in previous studies examining NPHP protein interactions .

• Developmental pathway analysis: Investigate how NPHP3 dysfunction affects developmental signaling pathways using a combination of NPHP3 antibody detection and pathway-specific markers, particularly in models of situs inversus or congenital heart defects .

• Mutation impact assessment: Compare NPHP3 protein levels and localization in models with different mutation types (e.g., missense vs. truncating) to correlate genotype with molecular phenotype.

This multi-faceted approach can provide comprehensive insights into how NPHP3 dysfunction contributes to the diverse manifestations of ciliopathies.

What approaches can I use to study NPHP3 interactions with other proteins?

Investigating NPHP3 protein interactions requires carefully optimized methodologies due to its localization in specialized cellular compartments. Consider these approaches:

• Co-immunoprecipitation (Co-IP): Use NPHP3 antibody for immunoprecipitation from tissue or cell lysates as demonstrated successfully with mouse testis tissue . For Co-IP experiments:

  • Use mild lysis conditions (1% Triton X-100) to preserve protein complexes

  • Add protease and phosphatase inhibitors to the lysis buffer

  • Optimize antibody concentration (0.5-4.0 μg per 1-3 mg of total protein)

  • Include appropriate negative controls (IgG, irrelevant antibody)

• Proximity ligation assay (PLA): This technique allows visualization of protein interactions in situ with high sensitivity and specificity. Combine NPHP3 antibody with antibodies against suspected interaction partners.

• FRET/BRET analysis: For live-cell interaction studies, combine fluorescently tagged NPHP3 with potential interaction partners and measure energy transfer.

• Yeast two-hybrid screening: While not directly using the antibody, this approach can identify potential interaction partners that can later be validated using the NPHP3 antibody.

• Mass spectrometry following immunoprecipitation: Use NPHP3 antibody for immunoprecipitation followed by mass spectrometry to identify novel interaction partners, as demonstrated in previous studies of nephrocystin protein complexes .

• GST pull-down assays: Use purified GST-tagged NPHP3 domains to identify direct binding partners, then confirm interactions using the antibody in cellular contexts.

When reporting interaction studies, it's essential to validate findings with multiple approaches and address potential limitations of each method.

How can I use NPHP3 antibody to study embryonic development and left-right asymmetry?

NPHP3 plays a critical role in embryonic development, with complete loss of function resulting in situs inversus and embryonic lethality in mice . To investigate these developmental roles:

• Developmental timing analysis: Use NPHP3 antibody to track protein expression throughout embryonic development in model organisms. Immunostaining of sectioned embryos at different developmental stages can reveal temporal regulation of NPHP3 expression.

• Node and lateral plate mesoderm staining: Since left-right asymmetry is established at the embryonic node, use immunofluorescence with NPHP3 antibody (1:20-1:200 dilution) to examine protein localization in nodal cilia and lateral plate mesoderm.

• Co-localization with laterality markers: Combine NPHP3 antibody staining with markers of left-right asymmetry (e.g., Nodal, Lefty, Pitx2) to understand how NPHP3 dysfunction affects asymmetry signaling pathways.

• Heterotaxia model validation: In models of randomized left-right asymmetry, use NPHP3 antibody to confirm altered protein expression or localization, correlating molecular findings with anatomical phenotypes.

• Heart development analysis: Given the congenital heart defects observed in NPHP3-deficient models , use immunohistochemistry with NPHP3 antibody in developing cardiac tissues to examine expression patterns during heart morphogenesis.

• Primary cilia visualization: Combine NPHP3 antibody with ciliary markers to investigate whether ciliary structure or function is compromised in specific embryonic tissues.

• Conditional knockout analysis: In conditional NPHP3 knockout models, use the antibody to confirm tissue-specific deletion and correlate with developmental outcomes.

Remember that embryonic tissue often requires specialized fixation and antigen retrieval methods for optimal antibody staining. For paraffin-embedded embryonic tissue, TE buffer (pH 9.0) is recommended for antigen retrieval .

Why might I observe different molecular weights for NPHP3 in Western blot?

Variations in observed molecular weight for NPHP3 can occur for several technical and biological reasons:

• Expected weight range: The published observed molecular weight for NPHP3 is 145-151 kDa, while the calculated weight based on amino acid sequence is 151 kDa (1330 amino acids) . Minor variations within this range are normal.

• Post-translational modifications: NPHP3 may undergo tissue-specific phosphorylation, glycosylation, or other modifications that can alter migration patterns. These modifications may be functionally relevant and should be documented rather than dismissed as artifacts.

• Alternative splicing: The presence of splice variants may result in detection of lower molecular weight bands. The NPHP3 gene is known to have multiple exons (27 exons) , creating potential for alternative splicing events.

• Proteolytic cleavage: Sample preparation without adequate protease inhibitors may result in partial degradation and lower molecular weight bands.

• Gel percentage and running conditions: Higher percentage gels may cause compression of high molecular weight proteins, affecting apparent molecular weight. Similarly, extended run times can improve resolution but may alter apparent molecular weight.

• Reducing vs. non-reducing conditions: Ensure consistent use of reducing agents in sample preparation, as their absence can affect protein conformation and migration.

• Protein standards: Verify calibration of protein standards and consider using high molecular weight-specific markers for improved accuracy in this range.

How can I improve signal intensity in NPHP3 immunohistochemistry?

Optimizing signal intensity for NPHP3 immunohistochemistry requires attention to several technical aspects:

• Antigen retrieval optimization: For paraffin-embedded tissues, the recommended method is TE buffer at pH 9.0, though citrate buffer at pH 6.0 may also be effective as an alternative . Optimal retrieval times and temperatures may vary by tissue type.

• Antibody concentration adjustment: While the recommended dilution range is 1:20-1:200 , start with a 1:50 dilution for initial tests, then adjust based on signal-to-noise ratio. For tissues with lower expression, higher antibody concentrations may be necessary.

• Incubation conditions: Extend primary antibody incubation to overnight at 4°C to enhance binding while maintaining specificity. Ensure consistent temperature control during incubation.

• Detection system selection: For challenging samples, consider signal amplification methods such as tyramide signal amplification (TSA) or polymer-based detection systems that provide greater sensitivity than standard ABC methods.

• Tissue preparation optimization: Ensure proper fixation times (typically 24-48 hours in 10% neutral buffered formalin) and complete paraffin infiltration. Overfixation can mask epitopes, while underfixation can compromise tissue morphology.

• Blocking optimization: Test different blocking solutions (BSA, normal serum, commercial blockers) to reduce background while preserving specific signal. For tissues with high endogenous biotin, use biotin-avidin blocking steps.

• Fresh antibody preparation: Avoid repeated freeze-thaw cycles of antibody aliquots, as this can reduce binding efficiency. Prepare fresh dilutions for each experiment.

• Positive control inclusion: Always run parallel staining with positive control tissue (human heart tissue has been validated) to confirm that negative results reflect biological reality rather than technical limitations.

By systematically optimizing these parameters, you can achieve consistent and specific staining for NPHP3 across different tissue types.

How should I interpret contradictory results between detection methods for NPHP3?

When facing contradictory results between different detection methods for NPHP3, consider these interpretive approaches:

Apparent contradictions often reveal important biological insights rather than technical failures, particularly for proteins with complex regulation and localization patterns like NPHP3.

How can NPHP3 antibody be used to characterize nephronophthisis disease models?

NPHP3 antibody provides powerful tools for characterizing nephronophthisis disease models, offering insights into molecular mechanisms and potential therapeutic targets:

• Mutation-specific effects: Using the NPHP3 antibody, researchers can determine how different mutations affect protein expression, stability, and localization. This is particularly relevant as hypomorphic NPHP3 mutations cause isolated nephronophthisis, while complete loss of function results in more severe phenotypes .

• Mouse model validation: The antibody has been validated in mouse models including the polycystic kidney disease (pcy) mouse model containing a hypomorphic Nphp3 mutation . Western blot analysis with NPHP3 antibody (1:500-1:2000 dilution) can confirm reduced protein expression in these models.

• Renal cyst formation analysis: Immunohistochemistry with NPHP3 antibody can reveal altered protein localization in cyst-lining epithelial cells, potentially identifying mechanism-based subgroups of nephronophthisis.

• Ciliary morphology correlation: Combined immunofluorescence for NPHP3 and ciliary markers can determine whether specific mutations affect ciliary structure, NPHP3 ciliary targeting, or both.

• Progression biomarkers: By analyzing NPHP3 expression patterns at different disease stages, researchers may identify molecular changes that precede clinical manifestations, potentially offering early disease markers.

• Compound heterozygosity analysis: In models with compound heterozygous mutations (similar to many human cases), the antibody can help determine how different mutation combinations affect protein function.

• Therapeutic response monitoring: Following experimental treatments, NPHP3 antibody can assess whether interventions restore normal protein expression or localization patterns.

• Multi-organ assessment: Beyond the kidney, NPHP3 antibody enables examination of protein expression in other affected organs, such as liver and retina in Senior-Loken syndrome patients , providing insights into tissue-specific manifestations.

These applications make NPHP3 antibody an essential tool for nephronophthisis research, enabling mechanistic studies that extend from molecular characterization to potential therapeutic development.

What can NPHP3 localization patterns reveal about ciliary function?

NPHP3 localization patterns provide critical insights into ciliary function and dysfunction in normal and disease states:

• Normal localization profile: NPHP3 has been observed at the base and lower half of cilia in serum-starved hTERT-RPE1 cells using immunofluorescence . This specific localization pattern suggests NPHP3 may regulate protein entry into the ciliary compartment or participate in transition zone functions.

• Transition zone architecture: The transition zone serves as a ciliary gate controlling protein composition. NPHP3 localization to this region suggests it may participate in regulating the ciliary proteome, with altered localization potentially indicating compromised ciliary compartmentalization.

• Cell-type specific patterns: Compare NPHP3 localization across different ciliated cell types using immunofluorescence (1:20-1:200 dilution) to determine whether its distribution varies with ciliary function (e.g., motile vs. primary cilia).

• Developmental dynamics: By examining NPHP3 localization throughout ciliogenesis (ciliary assembly), researchers can determine when and how the protein is recruited to cilia, providing insights into its function during ciliary formation.

• Co-localization analysis: Combine NPHP3 antibody with markers for different ciliary subdomains (axoneme, basal body, transition fibers) to precisely map its distribution. This can be accomplished using multi-color immunofluorescence in cells like hTERT-RPE1 where NPHP3 antibody has been validated .

• Mutagenesis impact: Compare localization patterns of wild-type NPHP3 with disease-associated mutants to determine whether specific mutations disrupt ciliary targeting.

• Interaction partner co-distribution: Analyze whether NPHP3 co-localizes with its interaction partners, providing functional insights. Co-immunoprecipitation experiments have identified NPHP3 interaction networks whose co-localization can be examined.

• Ciliopathy correlations: In models of different ciliopathies, examine whether NPHP3 mislocalization correlates with specific disease manifestations, potentially revealing mechanism-based disease classifications.

By carefully analyzing NPHP3 localization patterns using validated antibodies, researchers can gain significant insights into normal ciliary function and how its disruption contributes to human disease.